13:39 uur 16-03-2022

Exscientia rapporteert financiële resultaten over het vierde kwartaal en het einde van het jaar 2021 op 23 maart 2022

Bedrijf organiseert conference call en webcast op 24 maart 2022 om 12:30 uur GMT / 8:30 uur ET

OXFORD, Engeland–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) zal op woensdag 23 maart 2022 na sluiting van de Amerikaanse markt financiële resultaten rapporteren voor het vierde kwartaal en het volledige jaar eindigend op 31 december 2021. Na de aankondiging zal het bedrijf om 12.30 uur een telefonische vergadering en webcast houden. GMT / 8:30 uur ET op donderdag 24 maart 2022, om een overzicht te geven van het unieke end-to-end technologieplatform van het bedrijf en het werk van Exscientia om de ontdekking en ontwikkeling van geneesmiddelen volledig te automatiseren.

Exscientia to Report Fourth Quarter and Year End 2021 Financial Results on March 23, 2022

Company to host conference call and webcast on March 24, 2022 at 12:30 p.m. GMT / 8:30 a.m. ET

OXFORD, England–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2021, on Wednesday, March 23, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. ET on Thursday, March 24, 2022, to provide an overview of the company’s unique end-to-end technology platform and Exscientia’s work to fully automate drug discovery and development.

A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 (203) 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Vienna, Dundee, Boston, Miami, Cambridge (UK) and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.


Sara Sherman


Amanda Galgay


Check out our twitter: @NewsNovumpr